Insight, China's Pharmaceutical Industry

Company Medical Device

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results

Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced the commercial launch of AXELIOS 1, its...

Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced a strategic agreement with the ADAP Crisis...

Company Deals

Ipsen to Acquire Kartos Therapeutics for $450M Upfront, Adding Investigational MDM2 Inhibitor Navtemadlin to Myelofibrosis Pipeline

Fineline Cube Jun 30, 2026

Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) and Kartos Therapeutics announced a definitive merger agreement under...

Legal / IP

Biocytogen Prevails in Shanghai IP Court as Harbour BioMed Patent Infringement Claims Dismissed – RenNano Platform Cleared of Antibody Technology Violations

Fineline Cube Jun 30, 2026

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced it has received a favorable...

Company Medical Device

Innovative Medical Management Subsidiary Cereblink Secures Registration for AM5 Upper Limb Rehabilitation Exoskeleton – EMG-Driven System Targets CNS Injury Recovery

Fineline Cube Jun 30, 2026

Innovative Medical Management Co., Ltd. (SHE: 002173) announced that its holding subsidiary Cereblink (Hangzhou) Technology...

Company Drug

Hua Medicine Completes Greater China Rollout as Dorzagliatin Gains Macau Approval – First-in-Class Glucokinase Activator Now Available Across All Chinese Territories

Fineline Cube Jun 30, 2026

Hua Medicine (HKG: 2552) announced that the Pharmaceutical Administration Bureau of the Macau Special Administrative...

Company Drug

AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older

Fineline Cube Jun 29, 2026

AbbVie (NYSE: ABBV) announced on June 26, 2026, that the U.S. Food and Drug Administration...

Company Drug

Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval

Fineline Cube Jun 29, 2026

Akeso Biopharma (HKG: 9926) announced on June 26, 2026, that Qiyoukang (gumokimab, AK111) has completed...

Company Drug

Eli Lilly’s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use

Fineline Cube Jun 29, 2026

Eli Lilly and Company (NYSE: LLY) announced on June 26, 2026, that the European Medicines...

Company Deals

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

Fineline Cube Jun 29, 2026

Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that its board of...

Company Drug

J&J’s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line

Fineline Cube Jun 29, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced on June 26, 2026, that the Committee for...

Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026

China’s Center for Drug Evaluation (CDE) has released the 108th batch of reference preparations for...

Policy / Regulatory

NHSA Advances Record 674 Drugs in 2026 Insurance Catalog Review with 92% Preliminary Pass Rate

Fineline Cube Jun 29, 2026

China’s National Healthcare Security Administration (NHSA) released preliminary formal review results for the 2026 National...

Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Fineline Cube Jun 25, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that China’s National Medical Products Administration (NMPA)...

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026

The Department of Health – Abu Dhabi (DoH) has signed a memorandum of understanding (MoU)...

Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Fineline Cube Jun 25, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that China’s National Medical Products Administration...

Company Drug

Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients

Fineline Cube Jun 25, 2026

Gilead Sciences, Inc. (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorization...

Company Drug

Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications

Fineline Cube Jun 25, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) and Organon Canada announced the official commercial launch of...

Company Drug

AbbVie’s SKYRIZI (Risankizumab) Secures European Commission Approval for Pediatric Plaque Psoriasis – First IL-23 Inhibitor Authorized for Children as Young as Six

Fineline Cube Jun 25, 2026

AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for...

Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026

Shenzhen YHLO Biotech Co., Ltd. and Beijing Jingyi Bio have formally signed a comprehensive cooperation...

Insight, China's Pharmaceutical Industry

Novo Nordisk Names AWS Preferred Cloud Provider and Strategic AI Partner to Accelerate Drug Discovery With Agentic AI

Xbiome and BioMap Sign Strategic Cooperation Agreement to Advance AI‑Powered Microbiome Drug and Probiotic Product R&D

BeOne Medicines and Revolution Medicines Announce Clinical Collaboration and Regional Licensing Deal on RAS(ON) Inhibitors Across Select Asian Markets

Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL

Xtalpi and Gan & Lee Pharmaceuticals’ AI Peptide Delivery Lab Recognized as Beijing Key Laboratory, Deepening AI‑Powered Peptide Drug R&D Collaboration

BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities

Astellas Submits NDA in Japan for Fezolinetant, a First-in-Class Nonhormonal NK3 Receptor Antagonist for Menopausal Vasomotor Symptoms

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Ipsen to Acquire Kartos Therapeutics for $450M Upfront, Adding Investigational MDM2 Inhibitor Navtemadlin to Myelofibrosis Pipeline

Biocytogen Prevails in Shanghai IP Court as Harbour BioMed Patent Infringement Claims Dismissed – RenNano Platform Cleared of Antibody Technology Violations

Innovative Medical Management Subsidiary Cereblink Secures Registration for AM5 Upper Limb Rehabilitation Exoskeleton – EMG-Driven System Targets CNS Injury Recovery

Hua Medicine Completes Greater China Rollout as Dorzagliatin Gains Macau Approval – First-in-Class Glucokinase Activator Now Available Across All Chinese Territories

AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older

Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval

Eli Lilly’s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

J&J’s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

NHSA Advances Record 674 Drugs in 2026 Insurance Catalog Review with 92% Preliminary Pass Rate

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients

Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications

AbbVie’s SKYRIZI (Risankizumab) Secures European Commission Approval for Pediatric Plaque Psoriasis – First IL-23 Inhibitor Authorized for Children as Young as Six

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

You Missed

Novo Nordisk Names AWS Preferred Cloud Provider and Strategic AI Partner to Accelerate Drug Discovery With Agentic AI

Xbiome and BioMap Sign Strategic Cooperation Agreement to Advance AI‑Powered Microbiome Drug and Probiotic Product R&D

BeOne Medicines and Revolution Medicines Announce Clinical Collaboration and Regional Licensing Deal on RAS(ON) Inhibitors Across Select Asian Markets

BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities